UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

----- X

FEDERAL TRADE COMMISSION, STATE OF NEW:
YORK, STATE OF CALIFORNIA, STATE OF:
OHIO, COMMONWEALTH OF PENNSYLVANIA,:
STATE OF ILLINOIS, STATE OF NORTH:
CAROLINA, and COMMONWEALTH OF:
VIRGINIA,:

OPINION AND ORDER

20cv00706 (DLC)

Plaintiffs,

-v-

VYERA PHARMACEUTICALS, LLC, AND

PHOENIXUS AG, MARTIN SHKRELI,

individually, as an owner and former

director of Phoenixus AG and a former

executive of Vyera Pharmaceuticals,

LLC, and KEVIN MULLEADY, individually,

as an owner and former director of

Phoenixus AG and a former executive of:

Vyera Pharmaceuticals, LLC,

Defendants.

----- X

## APPEARANCES:

For plaintiff Federal Trade Commission:
James H. Weingarten
Markus H. Meier
Bradley S. Albert
Amanda Triplett
Armine Black
Daniel W. Butrymowicz
J. Maren Schmidt
Lauren Peay
Leah Hubinger
Matthew B. Weprin
Neal J. Perlman
Federal Trade Commission
600 Pennsylvania Avenue, NW
Washington, DC 20580

For plaintiff State of New York:

Amy E. McFarlane
Jeremy R. Kasha
Elinor R. Hoffman
Saami Zain
Office of the New York Attorney General
Antitrust Bureau
28 Liberty Street, 20th Floor
New York, NY 10005

Bryan Lewis Bloom Freshfields Bruckhaus Deringer US LLP 700 13th St. NW 10th fl. Washington, DC 20005

For plaintiff State of California: Michael D. Battaglia Office of the Attorney General of California 455 Golden Gate Avenue, Suite 11000 San Francisco, CA 94102

For plaintiff State of Ohio: Beth Finnerty Office of the Ohio Attorney General 150 E. Gay Street, 22nd Floor Columbus, OH 43215

For plaintiff Commonwealth of Pennsylvania: Joseph Betsko Pennsylvania Office of Attorney General Strawberry Square, 14th Floor Harrisburg, PA 17120

For plaintiff State of Illinois: Richard S. Schultz Office of the Attorney General of Illinois 100 W. Randolph Street, 11th Floor Chicago, IL 60601

For plaintiff State of North Carolina: K.D. Sturgis
Jessica V. Sutton
North Carolina Dept. of Justice
Consumer Protection Division
114 West Edenton Street
Raleigh, NC 27603

For plaintiff Commonwealth of Virginia:

Sarah Oxenham Allen Tyler T. Henry Office of the Attorney General of Virginia 202 North Ninth Street Richmond, VA 23219

For defendants Vyera Pharmaceuticals, LLC and Phoenixus AG: Stacey Anne Mahoney Sarah E. Hsu Wilbur Morgan, Lewis & Bockius LLP 101 Park Avenue New York, NY 10178

Scott A. Stempel
William Cravens
Melina R. Dimattio
Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004

Steven A. Reed Morgan, Lewis & Bockius LLP 1701 Market Street Philadelphia, PA 19103

Noah J. Kaufman Morgan, Lewis & Bockius LLP One Federal Street Boston, MA 02210

Michael M. Elliott Rachel J. Rodriguez Phillips Nizer LLP 485 Lexington Avenue New York, NY 10017

Michael L. Weiner Dechert LLP (NYC) 1095 Avenue of the Americas New York, NY 10036-6797

For defendant Martin Shkreli: Christopher H. Casey Andrew J. Rudowitz Jeffrey S. Pollack Sarah O'Laughlin Kulik Duane Morris LLP 30 South 17th Street Philadelphia, PA 19103

Sarah Fehm Stewart Duane Morris, LLP (NJ) One Riverfront Plaza, Suite 1800 Newark, NJ 07102-3889

For defendant Kevin Mulleady:
Kenneth R. David
Albert Shemtov Mishaan
Nicholas Anthony Rendino
Kasowitz, Benson, Torres LLP (NYC)
1633 Broadway
New York, NY 10019

DENISE COTE, District Judge:

Trial in this antitrust action is scheduled to begin on December 14, 2021. Plaintiffs have moved to preclude certain deposition testimony which the Defendants seek to offer at trial, specifically Rule 30(b)(6) testimony from third-party deponents to the extent that the testimony is not based on the personal knowledge of the witness. The motion is granted.

## Background

At this trial, the Plaintiffs will seek to prove that Vyera Pharmaceuticals, LLC and its parent company Phoenixus AG (together, "Vyera") and the two individual defendants violated the antitrust laws through a scheme that closed the distribution system of the Defendants' branded pharmaceutical Daraprim and blocked or delayed competition to Daraprim by generic pharmaceuticals. Defendants argue, in part, that the challenged

conduct did not delay generic competition and that the Plaintiffs' proposed relevant market is improperly defined. In support of their arguments, Defendants seek to offer Rule 30(b)(6) deposition testimony from several third-party corporate designees. The Rule 30(b)(6) testimony includes, in part, discussions regarding the production of generic pyrimethamine, the active pharmaceutical ingredient ("API") of Daraprim, and the potential for compounded pyrimethamine to serve as an alternative to FDA-approved pyrimethamine.

## Discussion

Under Rule 30(b)(6) of the Federal Rules of Civil

Procedure, during the discovery period "a party may name as the deponent a public or private corporation" and "[t]he named organization must designate one or more officers, directors, or managing agents, or designate other persons who consent to testify on its behalf. . . . The persons designated must testify about information known or reasonable available to the organization." Fed. R. Civ. P. 30(b)(6). Those testifying on behalf of the corporation must "be able to give complete, knowledgeable and binding answers." Keepers, Inc. v. City of Milford, 807 F.3d 24, 32 (2d Cir. 2015)(citation omitted). "[A]n organization's deposition testimony is binding in the sense that whatever its deponent says can be used against the organization." Id. at 34.

Under Rule 32(a)(1)(B) of the Federal Rules of Civil

Procedure, deposition testimony may be admitted against a party opponent at trial if it "would be admissible under the Federal Rules of Evidence if the deponent were present and testifying."

Fed. R. Civ. Pro. 32(a)(1)(B). The Federal Rules of Evidence provide that "[a] witness may testify to a matter only if evidence is introduced sufficient to support a finding that the witness has personal knowledge of the matter." Fed. R. Evid.

602. Personal knowledge is "a foundational requirement for fact witness testimony and is premised on the common law belief that a witness who testifies to a fact which can be perceived by the senses must have had an opportunity to observe, and must have actually observed the fact." United States v. Cuti, 720 F.3d 453, 458 (2d Cir. 2013) (citation omitted).

This personal knowledge requirement extends to Rule 30(b)(6) trial testimony when the corporation that responded to the Rule 30(b)(6) subpoena is not a party at the trial. As explained in an authoritative treatise, although a witness has testified as the representative of the corporation during a Rule 30(b)(6) deposition, the testimony is not admissible at trial without a "showing that the witness had personal knowledge of the matters discussed in the deposition." 8A Charles Alan

Wright & Arthur R. Miller & Richard L. Marcus, <u>Federal Practice</u> and Procedure § 2143 n.1 (3d ed).

Here, Plaintiffs seek to exclude portions of Rule 30(b)(6) depositions taken of ten corporate designees that have been designated by the Defendants as trial testimony. Unless the deponents were competent to testify about the matters discussed in the designations based on their personal knowledge, the designated portions must be stricken. The deposition testimony designated by the Defendants must be admissible under the Federal Rules of Evidence just as if the deponent were testifying in person at trial.

The Defendants do not contend, as a general matter, that they established during the depositions that the witnesses had personal knowledge of the topics to which they testified as corporate representatives. It appears, based on the parties' motion papers, that the Defendants subpoenaed the witnesses as corporate representatives and made little or no attempt to identify which if any portions of the testimony they elicited

<sup>&</sup>lt;sup>1</sup> The Plaintiffs have presented their objections to six of the ten depositions in an Appendix A to this motion and objected as well to the Defendants' designations of deposition testimony that are attached to the Pretrial Order.

<sup>&</sup>lt;sup>2</sup> The Defendants used only a third of the hours allotted to them for depositions in this case. They have made no argument that they did not have a sufficient opportunity to obtain relevant testimony from witnesses with personal knowledge.

during the Rule 30(b)(6) deposition were based on the witness' personal knowledge. The Defendants, as proponents of the evidence bear the burden of showing its admissibility. It is their burden to establish that their designated third-party testimony is admissible as based on the witness' personal knowledge. Unless the Defendants can point to evidence that the deponent was testifying based on personal knowledge and not simply as the corporate designee for the deposition, the testimony must be stricken. And, the testimony must be stricken if it is unclear whether the witness had personal knowledge of the events the witness recited or the processes the witness described.

The Defendants oppose this motion with several arguments. They contend that certain testimony is admissible because the witness testified that she had reviewed the Rule 30(b)(6) topics and was prepared to testify to all of them. This is insufficient to establish that the witness is competent to testify as a trial witness on those topics.

The Defendants next contend that other admissible evidence supports a finding that the deponent was testifying from personal knowledge during the Rule 30(b)(6) deposition. While the Defendants should have established a witness' personal knowledge during the deposition, if the Defendants can point to other admissible evidence establishing that the witness was

personally involved in the events at issue such that it would be reasonable to conclude that the deposition testimony on the topic was given from that personal knowledge, the testimony may be admissible. To the extent, however, that the Defendants seek to offer otherwise incompetent deposition testimony because the facts to which the deponent testified were confirmed by other admissible evidence, their application is denied. The confirmatory evidence must show that the witness has personal knowledge.

Finally, the Defendants appear to argue that the testimony is admissible because the Defendants never advised the witnesses during their depositions that their testimony should be based solely on their Rule 30(b)(6) preparation and there is no reason to conclude from the deposition testimony itself that it was not based on personal knowledge. This is insufficient to lay a foundation for the admissibility of the testimony. As noted above, the burden is on the Defendants, as the proponents of the evidence, to establish that the proffered testimony is admissible as competent evidence based on personal knowledge. In the absence of such a showing, admissibility will not be presumed and the testimony is precluded.

## Conclusion

Plaintiffs' October 20, 2021 motion to preclude Rule 30(b)(6) testimony proffered by the Defendants as not based on

personal knowledge is granted without prejudice to the

Defendants making the following showing. By November 19, the

Defendants must identify to the Plaintiffs their basis for

contending that any of the designated Rule 30(b)(6) testimony of

the ten witnesses to which the Plaintiffs have objected was

based on personal knowledge. The parties shall thereafter

confer and by December 2, provide the Court with at most ten

exemplars representing any continuing dispute that they have on

this issue.

Dated:

New York, New York November 15, 2021

DENISE COTE

United \$tates District Judge